# Evaluation of Microfilaremic Individuals after Mass Drug Treatment with Ivermectin, Diethylcarbamazine, and Albendazole for Lymphatic Filariasis in Papua New Guinea

**Authors:** Joycelyn Salo, Simon Westby, Ronnie Wakol, Nelly Sanuku, Krufinta Bun, Moses Laman, Christopher L. King

PMC · DOI: 10.4269/ajtmh.24-0382 · The American Journal of Tropical Medicine and Hygiene · 2025-03-25

## TL;DR

This study examines why some people in Papua New Guinea remained infected with lymphatic filariasis after mass drug treatment, finding that most had not taken the medication as instructed.

## Contribution

The study identifies non-compliance as the main reason for persistent infection after mass drug administration in a specific region of PNG.

## Key findings

- 10 individuals remained microfilaremic after initial mass drug administration.
- Most of these individuals admitted to not taking the initial treatment.
- Retreatment successfully cleared microfilaremia in nearly all cases.

## Abstract

After mass drug administration (MDA) for lymphatic filariasis, which involved a single coadministered dose of ivermectin plus diethylcarbamazine and albendazole (IDA), concerns arose regarding individuals who remained microfilaremic. This situation raised questions about the efficacy of the drugs and whether some individuals had not ingested them. In East New Britain Province, Papua New Guinea (PNG), where 81.7% of the population received IDA, 10 individuals were found to have microfilaremia 12 months after the first round of MDA in an area that had a high baseline of microfilaremia (n = 29 microfilariae [Mf] positive pre-MDA). Of these 10 individuals, 7 reported having taken the IDA medication. When Mf detection was repeated 18 months later, all 10 individuals remained Mf positive. Additionally, three more Mf-positive household members were identified, and they also reported taking the IDA. These Mf-positive individuals were then retreated with IDA under direct observation. At 7 and/or 14 months after retreatment, all initially Mf-positive individuals, except for one, were found to be Mf free. Upon further questioning, it was revealed that all but one individual admitted to not taking the initial MDA. Thus, IDA effectively clears Mf in this region of PNG, and the persistent microfilaremia after MDA is primarily because of individuals failing to take the medications as prescribed.

## Linked entities

- **Chemicals:** diethylcarbamazine (PubChem CID 3052), albendazole (PubChem CID 2082)

## Full-text entities

- **Diseases:** Lymphatic Filariasis (MESH:D004605)
- **Chemicals:** Ivermectin (MESH:D007559), IDA (-), Albendazole (MESH:D015766), Diethylcarbamazine (MESH:D004049)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12139549/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12139549/full.md

## References

17 references — full list in the complete paper: https://tomesphere.com/paper/PMC12139549/full.md

---
Source: https://tomesphere.com/paper/PMC12139549